Navigation Links
Hikma CEO Interviewed on Half-Year 2011 Results
Date:8/25/2011

LONDON, August 25, 2011 /PRNewswire/ --

Hikma Pharmaceuticals reports lower-than-expected 3.2% increase in revenues for the first half but maintains its full-year outlook.

The international drug developer says that political unrest in the MENA region disrupted month-on-month sales in some key countries like Egypt and Tunisia.

In an interview with financial broadcaster http://www.cantos.com, Hikma CEO Said Darwazah says that production is back to normal and that in spite of difficulties the group managed to grow the business organically by 3% in the MENA region.

While the group's Multi-Source Injectables division, which was acquired from Baxter Healthcare last year, was impacted by transaction delays, Mr Darwazah remains confident the business "will be breaking even" by the fourth quarter.

Hikma's CEO also makes clear that further acquisitions in emerging markets are in the pipeline.  In the interview he reiterates full-year guidance of 7% organic growth and 20% overall business growth.

The interview and transcript are available now on http://www.cantos.com/company/Hikma%20Pharmaceuticals.

Cantos.com, the online financial broadcaster, features in-depth interviews, documentaries and webcasts with senior company executives. If you would like to contact us, please email amanda.alexander@cantos.com or phone +44-(0)207-936-1372.



'/>"/>
SOURCE Hikma Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. HIKMA - 2008 Preliminary Results Interview With CEO
2. Hikma - Half Year Results Interviews With CEO and CFO
3. Hikma Expands its Global Injectables Business - Live Webcast
4. Hikma Expands its Global Injectables Business Through the Acquisition of Baxter Healthcare Corporations Multi-Source Injectables Business
5. China Sky One Medical, Inc. Interviewed in The China Perspective
6. Access Pharmaceuticals CEO Interviewed on Financial Website
7. AstraZeneca CEO Interviewed on Q4 and Full-Year Results 2009
8. Cord Blood America CEO Matthew Schissler Interviewed on International Successes
9. Smith & Nephew CEO Interviewed on Q2 2011 Results
10. STALLERGENES: Strong Sales Growth in 1st Half-Year: up 12% Full-Year Guidance Maintained
11. STALLERGENES: 1st Half-Year 2009: Performance Ahead of Expectations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2017)... ... August 21, 2017 , ... ... for this two-part educational webinar, in which attendees will learn about the assembly ... factor composition. Along with an overview of the development and validation of new ...
(Date:8/17/2017)... ... August 17, 2017 , ... Cynvenio Biosystems, Inc., a ... the launch of a new breast cancer monitoring study in partnership with Saint ... the potential for early detection of recurrent breast cancer using LiquidBiopsy and natural ...
(Date:8/16/2017)... ... August 16, 2017 , ... ... delivery system, announced it has secured $2M in funding from an impressive group ... Carmen Innovations, and SVG Thrive Fund. With this investment, 3Bar is broadening availability ...
(Date:8/15/2017)... , ... August 15, 2017 , ... Kapstone Medical ... 10 years of successes helping medical technology companies and inventors develop and safeguard their ... renowned full-service national engineering firm with a portfolio of clients in the United States ...
Breaking Biology Technology:
(Date:4/4/2017)... 2017   EyeLock LLC , a leader of ... States Patent and Trademark Office (USPTO) has issued U.S. ... of an iris image with a face image acquired ... company,s 45 th issued patent. ... given the multi-modal biometric capabilities that have recently come ...
(Date:3/29/2017)... , March 29, 2017  higi, the health IT ... North America , today announced a ... the acquisition of EveryMove. The new investment and acquisition ... of tools to transform population health activities through the ... data. higi collects and secures data today ...
(Date:3/23/2017)... -- The report "Gesture Recognition and Touchless Sensing Market by Technology ... Forecast to 2022", published by MarketsandMarkets, the market is expected to be worth ... and 2022. Continue Reading ... ... ...
Breaking Biology News(10 mins):